Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415766229> ?p ?o ?g. }
- W2415766229 endingPage "1303" @default.
- W2415766229 startingPage "1303" @default.
- W2415766229 abstract "The role of cytoreductive nephrectomy in patients with metastatic renal cancer in the era of targeted therapy is uncertain.To establish the safety and efficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patients with metastatic clear cell renal cancer.Single-arm phase 2 study of 104 previously untreated patients with metastatic clear cell renal cancer recruited between June 2008 and October 2012 at cancer treatment centers with access to nephrectomy services. The minimum follow-up was 30 months.Patients received 12 to 14 weeks of preoperative pazopanib therapy prior to planned cytoreductive nephrectomy and continued pazopanib therapy after surgery. Treatment was stopped at disease progression.The primary end point was clinical benefit (using Response Evaluation Criteria in Solid Tumors, version 1.1) prior to surgery (at 12-14 weeks). Secondary end points included surgical complications, progression-free survival (PFS), overall survival (OS), and biomarker analysis.Of 104 patients recruited, 100 patients were assessable for clinical benefit prior to planned nephrectomy; 80 of 104 (76.9%) were men; median [interquartile range] age, 64 [56-71] years). Overall, 84 of 100 (84% [95% CI, 75%-91%]) gained clinical benefit before planned nephrectomy. The median reduction in the size of the primary tumor was 14.4% (interquartile range, 1.4%-21.1%). No patients were unable to undergo surgery as a result of local progression of disease. Nephrectomy was performed in 63 (61%) of patients; 14 (22%) reported surgical complications. The 2 most common reasons for not undergoing surgery were progression of disease (n = 13) and patient choice (n = 9). There was 1 postoperative surgical death. The median PFS and OS for the whole cohort were 7.1 (95% CI, 6.0-9.2) and 22.7 (95% CI, 14.3-not estimable) months, respectively. Patients with MSKCC poor-risk disease or progressive disease prior to surgery had a poor outcome (median OS, 5.7 [95% CI, 2.6-10.8] and 3.9 [95% CI, 0.5-9.1] months, respectively). Surgical complications were observed in 14 (22%) of the nephrectomies. Biomarker analysis from sequential tissue samples revealed a decrease in CD8 expression (20.00 vs 13.75; P = .05) and significant reduction in expression of von Hippel-Lindau tumor suppressor (100 vs 40; P < .001) and C-MET (300 vs 100; P < .001) and increased programmed cell death ligand 1 expression (0 vs 1.5; P < .001) in the immune component. No on-treatment biomarker correlated with response.Nephrectomy after upfront pazopanib therapy could be performed safely and was associated with good outcomes in patients with intermediate-risk metastatic clear cell renal cancer." @default.
- W2415766229 created "2016-06-24" @default.
- W2415766229 creator A5007496293 @default.
- W2415766229 creator A5007745751 @default.
- W2415766229 creator A5008920583 @default.
- W2415766229 creator A5012800133 @default.
- W2415766229 creator A5017669437 @default.
- W2415766229 creator A5041162872 @default.
- W2415766229 creator A5044299286 @default.
- W2415766229 creator A5047034789 @default.
- W2415766229 creator A5048434751 @default.
- W2415766229 creator A5048796030 @default.
- W2415766229 creator A5055156038 @default.
- W2415766229 creator A5062742458 @default.
- W2415766229 creator A5062800422 @default.
- W2415766229 creator A5066769987 @default.
- W2415766229 creator A5075038130 @default.
- W2415766229 creator A5076824581 @default.
- W2415766229 creator A5078099654 @default.
- W2415766229 creator A5082540763 @default.
- W2415766229 creator A5084664528 @default.
- W2415766229 creator A5087403121 @default.
- W2415766229 creator A5088951258 @default.
- W2415766229 creator A5091326535 @default.
- W2415766229 creator A5091372096 @default.
- W2415766229 date "2016-10-01" @default.
- W2415766229 modified "2023-10-18" @default.
- W2415766229 title "Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer" @default.
- W2415766229 cites W2010195819 @default.
- W2415766229 cites W2021256410 @default.
- W2415766229 cites W2072478300 @default.
- W2415766229 cites W2108389924 @default.
- W2415766229 cites W2109732202 @default.
- W2415766229 cites W2110697333 @default.
- W2415766229 cites W2115155004 @default.
- W2415766229 cites W2116661424 @default.
- W2415766229 cites W2116949558 @default.
- W2415766229 cites W2140659843 @default.
- W2415766229 cites W2143813821 @default.
- W2415766229 cites W2145969161 @default.
- W2415766229 cites W2162424705 @default.
- W2415766229 cites W2164317031 @default.
- W2415766229 cites W2222086386 @default.
- W2415766229 cites W2237254160 @default.
- W2415766229 cites W2316731546 @default.
- W2415766229 doi "https://doi.org/10.1001/jamaoncol.2016.1197" @default.
- W2415766229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27254750" @default.
- W2415766229 hasPublicationYear "2016" @default.
- W2415766229 type Work @default.
- W2415766229 sameAs 2415766229 @default.
- W2415766229 citedByCount "63" @default.
- W2415766229 countsByYear W24157662292016 @default.
- W2415766229 countsByYear W24157662292017 @default.
- W2415766229 countsByYear W24157662292018 @default.
- W2415766229 countsByYear W24157662292019 @default.
- W2415766229 countsByYear W24157662292020 @default.
- W2415766229 countsByYear W24157662292021 @default.
- W2415766229 countsByYear W24157662292022 @default.
- W2415766229 countsByYear W24157662292023 @default.
- W2415766229 crossrefType "journal-article" @default.
- W2415766229 hasAuthorship W2415766229A5007496293 @default.
- W2415766229 hasAuthorship W2415766229A5007745751 @default.
- W2415766229 hasAuthorship W2415766229A5008920583 @default.
- W2415766229 hasAuthorship W2415766229A5012800133 @default.
- W2415766229 hasAuthorship W2415766229A5017669437 @default.
- W2415766229 hasAuthorship W2415766229A5041162872 @default.
- W2415766229 hasAuthorship W2415766229A5044299286 @default.
- W2415766229 hasAuthorship W2415766229A5047034789 @default.
- W2415766229 hasAuthorship W2415766229A5048434751 @default.
- W2415766229 hasAuthorship W2415766229A5048796030 @default.
- W2415766229 hasAuthorship W2415766229A5055156038 @default.
- W2415766229 hasAuthorship W2415766229A5062742458 @default.
- W2415766229 hasAuthorship W2415766229A5062800422 @default.
- W2415766229 hasAuthorship W2415766229A5066769987 @default.
- W2415766229 hasAuthorship W2415766229A5075038130 @default.
- W2415766229 hasAuthorship W2415766229A5076824581 @default.
- W2415766229 hasAuthorship W2415766229A5078099654 @default.
- W2415766229 hasAuthorship W2415766229A5082540763 @default.
- W2415766229 hasAuthorship W2415766229A5084664528 @default.
- W2415766229 hasAuthorship W2415766229A5087403121 @default.
- W2415766229 hasAuthorship W2415766229A5088951258 @default.
- W2415766229 hasAuthorship W2415766229A5091326535 @default.
- W2415766229 hasAuthorship W2415766229A5091372096 @default.
- W2415766229 hasBestOaLocation W24157662292 @default.
- W2415766229 hasConcept C119060515 @default.
- W2415766229 hasConcept C121608353 @default.
- W2415766229 hasConcept C126322002 @default.
- W2415766229 hasConcept C126894567 @default.
- W2415766229 hasConcept C141071460 @default.
- W2415766229 hasConcept C143998085 @default.
- W2415766229 hasConcept C168563851 @default.
- W2415766229 hasConcept C203092338 @default.
- W2415766229 hasConcept C2777472916 @default.
- W2415766229 hasConcept C2778439243 @default.
- W2415766229 hasConcept C2779490328 @default.
- W2415766229 hasConcept C2780091579 @default.
- W2415766229 hasConcept C2780227381 @default.
- W2415766229 hasConcept C2781068499 @default.